ProMIS Neurosciences Inc. filings document a clinical-stage biotechnology issuer with common shares listed on the Nasdaq Capital Market and organized in Ontario, Canada. Formal disclosures cover PMN310 and related clinical or regulatory updates, operating results, financing arrangements, registered security status, and the company’s capital structure, including common shares, purchase warrants, pre-funded warrants, and share consolidation actions.
Proxy and 8-K filings record shareholder voting matters, director elections, independent auditor ratification, equity incentive plan proposals, board appointments, and other governance changes. The filing record also documents Nasdaq listing compliance matters, material definitive agreements, and financial condition disclosures connected to the company’s neurodegenerative-disease development programs.
PROMIS Neurosciences Inc. ownership disclosure: Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl report shared beneficial ownership of 954,082 common shares, representing 9.99% of the class based on 9,550,373 shares outstanding.
The filing explains that the 9,550,373 base includes 8,967,693 common shares outstanding as reported by the issuer and 582,680 shares exercisable from warrants held by the reporting persons, limited by a Beneficial Ownership Cap that prevents exercise beyond 9.99%. Great Point states it is investment manager to related funds (BVF and BOVF) and the Reporting Persons disclaim beneficial ownership of those fund shares except to the extent of pecuniary interest. The Reporting Persons executed a Joint Filing Agreement dated May 15, 2026.
ProMIS Neurosciences (PMN) Schedule 13G: Wellington Management Group LLP reports beneficial ownership of 895,871 shares of ProMIS common stock, representing 9.99% of the class. The position consists of 696,378 shares held directly by Wellington Biomedical Innovation Master Investors (Cayman) II L.P. and 199,493 shares issuable upon exercise of warrants. The filers state an exercise limitation excludes 496,885 warrant shares from beneficial ownership calculations to enforce a 9.99% ownership cap. The ownership percentage is calculated using 8,967,693 shares outstanding as of March 25, 2026 per the company’s 10-K.
ProMIS Neurosciences Inc. reported a Q1 2026 net loss of $8.2 million, or $1.26 per share, compared with a $7.3 million loss a year earlier, as it ramped investment in its Alzheimer’s program PMN310. Research and development expenses rose to $7.0 million, including $6.3 million for PMN310, while general and administrative costs declined to $1.7 million.
In January 2026 the company strengthened its balance sheet with $70.1 million of net proceeds from a private placement of common shares, pre-funded warrants, and common share warrants, lifting cash to $63.8 million and total assets to $67.4 million as of March 31, 2026. Management now expects existing cash and short-term investments to fund operations through 2027.
The Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer’s disease has enrolled 144 patients across 21 U.S. sites. The study, which has FDA Fast Track designation, is designed to assess safety, amyloid-related imaging abnormalities, biomarkers, and early clinical outcomes, with a blinded interim analysis anticipated in early third quarter 2026 and top-line data expected in early 2027.
ProMIS Neurosciences Inc. reported first quarter 2026 results and highlighted progress in its Alzheimer’s program PMN310. The company closed a financing of up to $175 million, contributing to cash of $63,814,345 and total assets of $67,411,571 as of March 31, 2026, compared with $9,182,421 a year earlier. Shareholders' equity improved to $60,717,572 from a deficit of $(1,258,592).
For the quarter, research and development expenses were $6,971,005 and general and administrative expenses were $1,673,890, leading to a net loss of $8,244,372, or $(1.26) per share. The Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer’s disease is fully enrolled, with a blinded 6‑month interim analysis anticipated in early Q3 2026 and topline data expected in early 2027.
ProMIS Neurosciences Inc. reports that the Reporting Persons' beneficial ownership has decreased to 181,632 Common Shares, representing 2.0% of the class based on 8,967,693 Common Shares outstanding as of March 25, 2026. The filing (Amendment No. 5) attributes these holdings to Michael S. Gordon and Title 19 Promis and describes prior private placements, warrant exercises and conversions—including exercised July 2024 warrants and currently exercisable July 2025 warrants—that underlie the reported position.
ProMIS Neurosciences Inc. director Patrick D. Kirwin reported an open-market purchase of Common Shares through an associated professional corporation. The entity bought 4,000 shares at $11.33 per share, and now holds 4,653 shares indirectly. Kirwin also holds 5,135 shares directly and 305 shares indirectly through his spouse.
ProMIS Neurosciences Inc. is holding its 2026 annual shareholder meeting as a virtual-only webcast on May 20, 2026 at 10:30 a.m. Eastern Time, with a record date of March 23, 2026. Shareholders will elect seven directors, ratify Baker Tilly US, LLP as independent auditor, and vote on an amendment to the 2025 Stock Option and Incentive Plan.
The board is not nominating director Patrick Kirwin for re-election and is putting forward Dr. Slanix Alex as an independent nominee. As of March 23, 2026, 8,967,693 common shares were outstanding, with significant holders including entities affiliated with Janus Henderson at 14.99%. The proxy also details board independence, committee structures, director compensation and a non-employee director pay and option policy.
Janus Henderson Group plc reported beneficial ownership of 1,292,757 common shares of PROMIS Neurosciences Inc. The filing (Schedule 13G) states this represents 14.4% of the class as of 03/31/2026 with shared voting and dispositive power over those shares. The filing is signed on 04/07/2026.